miR‑342 is associated with estrogen receptor‑α expression and response to tamoxifen in breast cancer

  • Authors:
    • Yue‑Jun He
    • Jian‑Zhong Wu
    • Ming‑Hua Ji
    • Tao Ma
    • En‑Qi Qiao
    • Rong Ma
    • Jin‑Hai Tang
  • View Affiliations

  • Published online on: January 22, 2013     https://doi.org/10.3892/etm.2013.915
  • Pages: 813-818
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Estrogen receptor‑α (ERα) is essential for estrogen‑dependent growth and its level of expression is a crucial determinant of response to endocrine therapy and prognosis in ERα‑positive breast cancer. Breast cancer patients show a wide range of ERα expression levels which change in individual patients during disease progression and in response to systemic therapies. However, little is known concerning how the expression of ERα is regulated in human breast cancer. Recently, several microRNAs (miRNAs) have been identified to regulate ERα expression and to predict ER, progesterone receptor (PR) and human epidermal growth factor 2 (HER2) status. The expression levels of miR‑342 and ERα mRNA were analyzed in human breast cancer samples and cell lines by quantitative reverse transcription (RT)‑PCR analysis. The correlations between the expression levels of miR‑342 and clinicopathological factors were analyzed. Statistically significant associations were observed between miR‑342 and ER, HER2 and vascular endothelial growth factor (VEGF) status in the human breast cancer samples and the levels of miR‑342 gradually increased as ERα mRNA expression increased. Moreover, ectopic overexpression of miR‑342 upregulated the expression levels of the ERα mRNA and significantly sensitized the MCF‑7 cells to tamoxifen‑induced apoptosis and inhibition of cellular proliferation. These results suggested that miR‑342 expression is positively correlated with ERα mRNA expression in human breast cancer and that it may be a significant marker for predicting tamoxifen sensitivity in ERα‑positive breast cancer and a potential target for restoring ERα expression and responding to antiestrogen therapy.
View Figures
View References

Related Articles

Journal Cover

March 2013
Volume 5 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
He YJ, Wu JZ, Ji MH, Ma T, Qiao EQ, Ma R and Tang JH: miR‑342 is associated with estrogen receptor‑α expression and response to tamoxifen in breast cancer. Exp Ther Med 5: 813-818, 2013
APA
He, Y., Wu, J., Ji, M., Ma, T., Qiao, E., Ma, R., & Tang, J. (2013). miR‑342 is associated with estrogen receptor‑α expression and response to tamoxifen in breast cancer. Experimental and Therapeutic Medicine, 5, 813-818. https://doi.org/10.3892/etm.2013.915
MLA
He, Y., Wu, J., Ji, M., Ma, T., Qiao, E., Ma, R., Tang, J."miR‑342 is associated with estrogen receptor‑α expression and response to tamoxifen in breast cancer". Experimental and Therapeutic Medicine 5.3 (2013): 813-818.
Chicago
He, Y., Wu, J., Ji, M., Ma, T., Qiao, E., Ma, R., Tang, J."miR‑342 is associated with estrogen receptor‑α expression and response to tamoxifen in breast cancer". Experimental and Therapeutic Medicine 5, no. 3 (2013): 813-818. https://doi.org/10.3892/etm.2013.915